Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

NCT06649695 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.

NCT NCT06649695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
Lead sponsor
European Myeloma Network B.V.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 2, 2025
Completion date
September 30, 2028
Enrollment
30 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis